HighTower Advisors
LUMO

HighTower Advisors’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

HighTower Advisors’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2,010
Closed -$804K – 1965
2015
Q2 		$804K Buy
+2,010
New +$854K 0.01% 847

Other funds holding LUMO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HighTower Advisors's LUMO Position: Q3 2015 in Review

HighTower Advisors sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2015, closing a stake of 2,010 shares — an estimated $804K sold.

HighTower Advisors first reported a position in LUMO in Q2 2015 and held it in 1 quarter. The position peaked at $804K in Q2 2015. 152 funds tracked by Wall St. Rank hold LUMO as of Q3 2015.

  • HighTower Advisors reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • HighTower Advisors sold 2,010 Lumos Pharma, Inc. Common Stock shares in Q3 2015, an estimated $804K.
  • HighTower Advisors first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2015 and held it in 1 quarter.
  • HighTower Advisors's Lumos Pharma, Inc. Common Stock position peaked at $804K in Q2 2015.
  • 152 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2015.

Based on HighTower Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.